Sir Philip Hampton will take over from Sir Christopher Gent as chairman of GlaxoSmithKline on May 7, nearly four months earlier than expected. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/earlier_start_for_new_gsk_chairman_hampton_971116Recordati is buying a 90% stake in Opalia Pharma of Tunisia in a deal valued at 80 million dinar, or around 37 million euros. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/recordati_acquires_tunisias_opalia_1005440Bayer has been given the green light by Europe's regulator to market its new long-term contraceptive Jaydess which provides prevention of pregnancy for up to three years. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/europe_approves_bayers_jaydess_976096Scottish diabetics with a condition that causes blurred or double vision will be cheered by the news that Alimera Sciences' Iluvien has been backed by the country's cost watchdog. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/smc_backs_alimera_eye_drug_1001518Spain's Almirall has set up an affiliate in Canada, which will provide a base for the firm's promotion plans for its recently-approved chronic obstructive pulmonary disease drug aclidinium. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/almirall_opens_canadian_hq_976682Watson Pharmaceuticals is being sued by Pfizer over its plans to market a generic version of the US giant's erectile dysfunction drug Viagra. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/watson_sued_over_generic_viagra_980937Roche has hit the acquisition trail again to buy privately-held Signature Diagnostics of Germany. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/roche_buys_german_genomics_group_signature_971024AstraZeneca says that Duaklir Genuair, from the Almirall respiratory portfolio it recently purchased, has been given the green light from regulators in Europe for chronic obstructive pulmonary disease. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/az_gets_eu_approval_for_copd_combo_1002809Eisai has filed its anticancer agent lenvatinib with regulators on both sides of the Atlantic. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/eisai_files_lenvatinib_for_thyroid_cancer_1002345As a bribery scandal continues to engulf GlaxoSmithKline in China, UCB has revealed that its offices have been visited by authorities this week. - News - PharmaTimes
by Kevin Grogan
www.pharmatimes.com/news/chinese_officials_inspect_ucb_offices_1005402
